New Study Shows Increases in RSV Hospitalization among High-Risk Preterm Infants
New Respiratory Syncytial Virus (RSV) Hospitalization Data from
2014-2015 RSV season compared to 2013-2014 RSV season presented at AMCP
Nexus 2016
WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca today announced new data demonstrating that respiratory
syncytial virus hospitalization (RSVH) rates increased significantly
during the 2014-2015 RSV season among US infants <3 months of age born
at 29-34 weeks gestational age (wGA), as compared to the 2013-2014
season.1 RSV is a contagious, seasonal respiratory virus that
can lead to a serious lung infection and hospitalization in high-risk
babies, particularly preterm infants.2,3,4 These data are
based on data from over 2.2 million US infants and represent the first
and only analysis conducted using national US Medicaid and Commercial
insurance claims databases to further understand the changes in both
immunoprophylaxis (IP) utilization and RSVH rates. This research was
presented as a poster (poster number J14) at the annual Academy of
Managed Care Pharmacy (AMCP) Nexus meeting in National Harbor, MD.
Results showed that among <3 months old infants who were born at 29-34
wGA, RSVH rates increased by 170% and 40% within the commercial and
Medicaid populations, respectively, during the 2014-2015 season when
compared to the prior season.1
-
RSVH rates for <6 months old infants who were born at 29-34 wGA were
2-7 times higher than RSVH rates for <6 months old infants who were
born full term in the 2014-2015 season.1
Dr. Leonard Krilov, pediatric infectious disease specialist,
Winthrop-University Hospital, said: “RSV disease, a leading cause of
hospitalization for babies in their first year of life in the United
States, can be especially severe during the first few months of life,
creating a significant burden on individual infants, their families and
the health care systems who treat these vulnerable patients. These data
emphasize the importance and risk of this disease in infants.”
IP use during the 2014-2015 season decreased by 45-94% and 65-95% among
commercial and Medicaid populations, respectively, versus the 2013-2014
season.1 The results are based on data that evaluate
independent changes in RSVH rates and IP utilization preceding and
following the 2014 American Academy of Pediatrics guidance.
RSVH rates and increases of RSVH rates in the 2014-2015 RSV season were
highest during the first three months in life for infants born at
earlier gestational ages.1 Dr. Krilov said: “These data
confirm that preterm infants – specifically those born at 29-34 wGA –
are at an increased risk for hospitalization for severe RSV disease.
Contributing new data to the scientific conversations among key industry
stakeholders allows us to further the conversation around severe RSV
disease both at this meeting and for future RSV seasons to come.”
NOTES TO EDITORS
About The Poster Presented at AMCP Nexus 2016 (poster number J14)
These data are comprised of an analysis of both RSVH rates and IP
utilization during the 2014-2015 RSV season versus the 2013-2014 RSV
season. The study evaluated 1.7 million Medicaid and 1.5 million
Commercial births from each respective database to assess outpatient IP
use and RSVH occurrences between November 2014 and March 2015. 1.2
million Medicaid and 1.0 million commercial preterm and full-term
infants without chronic lung disease or congenital heart disease were
selected from the databases using DRG and ICD-9-CM codes. RSVH rates
were calculated per 100 infant-seasons with Medicaid and Commercial
database infants weighted by prevalence of US births. To adjust for
seasonal variation, rate ratios for preterm infants were calculated
relative to full-term infants.
About RSV
RSV is a contagious, seasonal respiratory virus that nearly all children
will contract by the age of two and most will recover from within 1-2
weeks.2,3,4 In certain high-risk babies, however, RSV can
lead to a serious lung infection and hospitalization.6,7
Preterm infants are at increased risk of developing severe RSV disease
because their lung volume is significantly less than that of full-term
infants, and their airways are smaller and narrower than those of a baby
born at term.8
About Academy of Managed Care Pharmacy Nexus 2016 Meeting
The Academy of Managed Care Pharmacy (AMCP) Nexus 2016 Meeting is being
held from Monday, October 3rd to Thursday, October 6th
in National Harbor, MD. AMCP Nexus 2016 provides an educational space
for managed care professionals to discuss developments and issues in the
managed care pharmacy space.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialization of
prescription medicines, primarily for the treatment of diseases in three
therapy areas – Respiratory and Autoimmunity, Cardiovascular and
Metabolic Diseases, and Oncology. The company is also active in
inflammation, infection and neuroscience through numerous
collaborations. AstraZeneca operates in over 100 countries and its
innovative medicines are used by millions of patients worldwide. For
more information please visit: www.astrazeneca-us.com.
References
-
McLaurin K, Pavilack M, Krilov L, Diakun D, Wade S, Farr A. Poster
Number J14. Poster presented at Academy of Managed Care Pharmacy
(AMCP) Nexus 2016 Meeting, October 3-6 2016. -
Glezen WP, Taber LJ, Frank AL, Kasel JA. Risk of Primary Infection and
Reinfection with Respiratory Syncytial Virus. Am J Dis Child.
1986; 140:543-546. -
Centers for Disease Control and Prevention. Infection and Incidence. http://www.cdc.gov/rsv/about/infection.html.
Accessed June 26, 2015. -
Hall CB, Weinberg GA, Iwane MK, et al. The Burden of Respiratory
Syncytial Virus Infection in Young Children. N Engl J Med.
2009; 360:588-598. -
Leader S, Kohlhase K. Respiratory syncytial virus-coded pediatric
hospitalizations, 1997 to 1999. Pediatr Infect Dis J. 2002; 21:
629-632. -
Boyce TG, et al. Rates of hospitalizations for respiratory syncytial
virus infection among children in Medicaid. J Pediatr. 2000;
137:865-70. -
Centers for Disease Control and Prevention. Preterm Birth. http://www.cdc.gov/reproductivehealth/maternalinfanthealth/pretermbirth.htm.
Accessed June 26, 2015. -
Langston C, Kida K, Reed M, Thurlbeck WM. Human lung growth in late
gestation and in the neonate. Am Rev Respir Dis. 1984;
129:607-613.
Contacts
AstraZeneca
Michele Meixell, +1 302-885-2677
or
Abigail
Bozarth, +1 302-885-2677
